PPM1D as a novel biomarker for prostate cancer after radical prostatectomy

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 2919-2926

  Jiao, Li ^a,b   Shen, Dan ^b   Liu, Guanzhong ^b   Jia, Jiaoyuan ^c   Geng, Jinxia ^a   Wang, Haibo ^a   Sun, Yinghao ^b  

^a Department of Physiology Bethune Medical Officer School   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c JILIN UNIVERSITY   (China)

Author keywords

Biomarker; PPM1D; Prognosis; Prostate cancer

Indexed keywords

PHOSPHOPROTEIN PHOSPHATASE; PROTEIN PHOSPHATASE MAGNESIUM DEPENDENT 1 DELTA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PHOSPHOPROTEIN PHOSPHATASE 2C; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PROGNOSIS; CELL COUNT; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LNCAP CELL LINE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; APOPTOSIS; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; CELL MOTION; COMPARATIVE STUDY; DISEASE COURSE; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PPM1D; PROGNOSIS; PROSTATE TUMOR; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE; VERY ELDERLY; WESTERN BLOTTING;

BIOMARKER; PPM1D; PROGNOSIS; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHOSPHOPROTEIN PHOSPHATASES; PROGNOSIS; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84906309217     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Siegel R1, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A and Ward E: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241, 2012.
2. Hull GW1, Rabbani F, Abbas F, Wheeler TM, Kattan MW and Scardino PT: Cancer control with radical prostatectomy alone in 1, 000 consecutive patients. J Urol 167: 528-534, 2002.
3. Patel AR and Stephenson AJ: Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage? Nat Rev Urol 8: 385-392, 2011.
4. Mishra MV1, Champ CE, Den RB, Scher ED, Shen X, Trabulsi EJ, Lallas CD, Knudsen KE, Dicker AP and Showalter TN: Postprostatectomy radiation therapy: an evidence-based review. Future Oncol 7: 1429-1440, 2011.
5. Swanson GP and Basler JW: Prognostic factors for failure after prostatectomy. J Cancer 2: 1-19, 2010.
6. Crawford ED, Bennett CL, Andriole GL, Garnick MB and Petrylak DP: The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int 112: 548-560, 2003.
7. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M and Donehower LA: The type 2C phosphatase WIP1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 27: 123-135, 2008.
8. Shreeram S, Hee WK, Demidov ON, Kek C, Yamaguchi H, Fornace AJ Jr, Anderson CW, Appella E and Bulavin DV: Regulation of ATM/p53-dependent suppression of MYC-induced lymphomas by WIP1 phosphatase. J Exp Med 203: 2793-2799, 2006.
9. Bulavin DV1, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ Jr. and Appella E: Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31: 210-215, 2002.
10. Koom WS, Park SY, Kim W, Kim M, Kim JS, Kim H, Choi IK, Yun CO and Seong J: Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma. J Radiat Res 53: 202-210, 2012.
11. Bulavin DV1, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E and Fornace AJ Jr.: Inactivation of the WIP1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(INK4A)-p19(ARF) pathway. Nat Genet 36: 343-350, 2004.
12. Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, Rao PH, Donehower LA and Kim JY: Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 86: 245-256, 2008.
13. Saito-Ohara F1, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T and Inazawa J: PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 63: 1876-1883, 2003.
14. Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamazaki K, Kosuge T, Kanai Y, Hosoda F, Imoto I, Ohki M, Inazawa J and Hirohashi S: Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 98: 392-400, 2007.
15. Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A and Reis-Filho JS: PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 15: 2269-2280, 2009.
16. Yu E, Ahn YS, Jang SJ, Kim MJ, Yoon HS, Gong G and Choi J: Overexpression of the WIP1 gene abrogates the p38 MAPK/p53/WIP1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res Treat 101: 269-278, 2007.
17. Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjärvi T and Kallioniemi A: The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat 95: 257-263, 2006.
18. Satoh N, Maniwa Y, Bermudez VP, Nishimura K, Nishio W, Yoshimura M, Okita Y, Ohbayashi C, Hurwitz J and Hayashi Y: Oncogenic phosphatase WIP1 is a novel prognostic marker for lung adenocarcinoma patient survival. Cancer Sci 102: 1101-1106, 2011.
19. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ Jr. and Appella E: Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31: 210-215, 2002.
20. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, Nozawa S, Inazawa J and Imoto I: Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 9: 1995-2004, 2003.
21. Wang P, Rao J, Yang H, Zhao H and Yang L: WIP1 overexpression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas. J Surg Oncol 104: 679-684, 2011.
22. Hu W, Feng Z, Modica I, Klimstra DS, Song L, Allen PJ, Brennan MF, Levine AJ and Tang LH: Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway. Genes Cancer 1: 360-368, 2010.